Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RG 7112

Next Previous
Drug Profile

RG 7112

Alternative Names: R 1772; R-7112; RG-7112; RO-5045337

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto-oncogene protein c-mdm2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Haematological malignancies; Liposarcoma; Soft tissue sarcoma; Solid tumours

Most Recent Events

  • 26 Jun 2017 Roche completes a phase I trial in Haematological malignancies and Solid tumours in USA, Canada and France (NCT01677780)
  • 30 Nov 2013 Roche completes a phase I trial in Acute myeloid leukaemia (combination therapy) in USA, Canada, France, Italy and the UK (NCT01635296)
  • 25 Jul 2013 Discontinued - Phase-I for Acute myeloid leukaemia (combination therapy) in USA, Canada, France, Italy and United Kingdom (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top